JP2010500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500025A5
JP2010500025A5 JP2009523833A JP2009523833A JP2010500025A5 JP 2010500025 A5 JP2010500025 A5 JP 2010500025A5 JP 2009523833 A JP2009523833 A JP 2009523833A JP 2009523833 A JP2009523833 A JP 2009523833A JP 2010500025 A5 JP2010500025 A5 JP 2010500025A5
Authority
JP
Japan
Prior art keywords
nucleic acid
strand
pharmaceutical composition
seq
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009523833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500025A (ja
Filing date
Publication date
Priority claimed from US11/501,634 external-priority patent/US7902352B2/en
Application filed filed Critical
Publication of JP2010500025A publication Critical patent/JP2010500025A/ja
Publication of JP2010500025A5 publication Critical patent/JP2010500025A5/ja
Pending legal-status Critical Current

Links

JP2009523833A 2006-08-09 2007-08-08 霊長類ハンチントン遺伝子発現をinvivoで抑制する方法および配列 Pending JP2010500025A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/501,634 US7902352B2 (en) 2005-05-06 2006-08-09 Isolated nucleic acid duplex for reducing huntington gene expression
PCT/US2007/017638 WO2008021136A2 (en) 2006-08-09 2007-08-08 Methods and sequences to suppress primate huntington gene expression in vivo

Publications (2)

Publication Number Publication Date
JP2010500025A JP2010500025A (ja) 2010-01-07
JP2010500025A5 true JP2010500025A5 (enExample) 2011-10-20

Family

ID=39082580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523833A Pending JP2010500025A (ja) 2006-08-09 2007-08-08 霊長類ハンチントン遺伝子発現をinvivoで抑制する方法および配列

Country Status (5)

Country Link
US (1) US7902352B2 (enExample)
EP (1) EP2056881A4 (enExample)
JP (1) JP2010500025A (enExample)
CN (1) CN101557831A (enExample)
WO (1) WO2008021136A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
WO2005027980A1 (en) * 2003-09-12 2005-03-31 University Of Massachusetts Rna interference for the treatment of gain-of-function disorders
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP1885854B1 (en) 2005-05-06 2012-10-17 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
JP2009504782A (ja) 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
EP2647711B1 (en) 2006-11-29 2018-01-10 University of Iowa Research Foundation Alternative export pathways for vector expressed RNA interference
CA2688514A1 (en) 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2008150897A2 (en) 2007-05-31 2008-12-11 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN102124109B (zh) 2008-06-30 2013-10-16 Cho-A制药有限公司 猪α-S1-酪蛋白基因,其启动子及其用途
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
ES2759317T3 (es) 2014-05-20 2020-05-08 Univ Iowa Res Found Compuestos terapéuticos para la enfermedad de Huntington
US10450563B2 (en) * 2015-02-10 2019-10-22 Genzyme Corporation Variant RNAi
WO2017015575A1 (en) 2015-07-22 2017-01-26 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
JP2019516680A (ja) 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物およびその方法
IL273394B2 (en) 2017-09-22 2025-04-01 Genzyme Corp RNAI variant
IL307239A (en) 2021-03-29 2023-11-01 Alnylam Pharmaceuticals Inc Preparations containing Huntingtin IRNA factor (HTT) and methods of using them

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2181691B (en) 1985-10-21 1990-05-23 Porvair Ltd Gloves
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0586700A4 (en) 1991-05-24 1994-10-19 Sumitomo Pharma INSTRUMENT FOR APPLYING A MEDICINAL PRODUCT TO THE INSIDE OF THE BRAIN.
US5236908A (en) 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5354326A (en) 1993-01-27 1994-10-11 Medtronic, Inc. Screening cable connector for interface to implanted lead
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5849995A (en) 1993-09-27 1998-12-15 The University Of British Columbia Mouse model for Huntington's Disease and related DNA sequences
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
EP0734438A4 (en) 1993-12-17 1998-12-23 Spinal Cord Society METHOD FOR INDUCING DNA SYNTHESIS IN NEURONES
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5534350A (en) 1994-12-28 1996-07-09 Liou; Derlin Powerfree glove and its making method
US7069634B1 (en) 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5942455A (en) 1995-11-14 1999-08-24 Drexel University Synthesis of 312 phases and composites thereof
JPH09268067A (ja) 1996-03-29 1997-10-14 Asahi Glass Co Ltd 炭化ケイ素部材の製造方法
US7189222B2 (en) 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
WO2000062828A1 (en) 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US6281009B1 (en) 1996-09-11 2001-08-28 The General Hospital Corporation Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell
US5882561A (en) 1996-11-22 1999-03-16 Drexel University Process for making a dense ceramic workpiece
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US5968059A (en) 1997-03-06 1999-10-19 Scimed Life Systems, Inc. Transmyocardial revascularization catheter and method
GB9706463D0 (en) 1997-03-27 1997-05-14 Medical Res Council A model of inflamation in the central nervous system for use in the study of disease
WO1998046273A2 (en) 1997-04-17 1998-10-22 Paola Leone Delivery system for gene therapy to the brain
US5782892A (en) 1997-04-25 1998-07-21 Medtronic, Inc. Medical lead adaptor for external medical device
US5931861A (en) 1997-04-25 1999-08-03 Medtronic, Inc. Medical lead adaptor having rotatable locking clip mechanism
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6110459A (en) 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US6231969B1 (en) 1997-08-11 2001-05-15 Drexel University Corrosion, oxidation and/or wear-resistant coatings
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6151525A (en) 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
DE19938960A1 (de) 1998-03-10 2001-02-22 Bisping Hans Juergen Testkabelanordnung
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
EP1171588A4 (en) 1999-04-28 2002-06-26 Univ Leland Stanford Junior VECTOR FROM THE P ELEMENT AND METHOD FOR APPLYING IT
GB9928248D0 (en) 1999-12-01 2000-01-26 Gill Steven S An implantable guide tube for neurosurgery
US6310048B1 (en) 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
US6461989B1 (en) 1999-12-22 2002-10-08 Drexel University Process for forming 312 phase materials and process for sintering the same
US20030092003A1 (en) 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
EP1267946A4 (en) 2000-02-28 2008-07-02 Genesegues Inc SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6945969B1 (en) 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
US6551290B1 (en) 2000-03-31 2003-04-22 Medtronic, Inc. Catheter for target specific drug delivery
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
AU2001288317A1 (en) 2000-08-30 2002-03-13 Agion Technologies, Llc Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20050209179A1 (en) 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US6659995B1 (en) 2000-11-17 2003-12-09 Syde A. Taheri Autologous myocyte micro granual retrieval and implantation (AMMGRI)
CA2327208A1 (en) 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
EP1409737A4 (en) 2001-06-15 2005-10-12 Interleukin Genetics Inc METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING
CA2455424A1 (en) 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US6944497B2 (en) 2001-10-31 2005-09-13 Medtronic, Inc. System and method of treating stuttering by neuromodulation
US8274559B2 (en) * 2001-11-09 2012-09-25 Karl Storz Imaging, Inc. Replaceable hardware component of a camera control unit for video systems
US20030120282A1 (en) 2001-12-24 2003-06-26 Scouten Charles W. Stereotaxic manipulator with retrofitted linear scales and digital display device
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
US7270653B2 (en) 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
US20040023855A1 (en) 2002-04-08 2004-02-05 John Constance M. Biologic modulations with nanoparticles
US20040018520A1 (en) 2002-04-22 2004-01-29 James Thompson Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
WO2004010787A1 (ja) 2002-07-25 2004-02-05 Nissei Kabushiki Kaisha ロールコーン製造装置
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20050048641A1 (en) 2002-11-26 2005-03-03 Medtronic, Inc. System and method for delivering polynucleotides to the central nervous system
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
JP2004232811A (ja) 2003-01-31 2004-08-19 Hitachi Unisia Automotive Ltd 補機駆動用電磁クラッチ
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040186528A1 (en) 2003-03-20 2004-09-23 Medtronic, Inc. Subcutaneous implantable medical devices with anti-microbial agents for chronic release
US8512290B2 (en) 2003-03-20 2013-08-20 Boston Scientific Scimed, Inc. Devices and methods for delivering therapeutic or diagnostic agents
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
ES2562490T3 (es) 2003-05-01 2016-03-04 Genzyme Corporation Terapia génica para trastornos neurometabólicos
US7917228B2 (en) 2003-05-13 2011-03-29 Medtronic, Inc. Medical lead adaptor assembly
WO2004101787A1 (ja) 2003-05-14 2004-11-25 Japan Science And Technology Agency ハンチンチン遺伝子の発現抑制
US20060014165A1 (en) 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
WO2005027980A1 (en) 2003-09-12 2005-03-31 University Of Massachusetts Rna interference for the treatment of gain-of-function disorders
WO2005065242A2 (en) 2003-12-29 2005-07-21 Am Biosolutions Method of treating cancer using platelet releasate
US20050153353A1 (en) 2004-01-09 2005-07-14 Bernd Meibohm Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism
US20050202075A1 (en) 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
US7498316B2 (en) 2004-04-06 2009-03-03 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using RNA interference
EP1735443A2 (en) 2004-04-14 2006-12-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
WO2006022639A1 (en) 2004-07-21 2006-03-02 Applera Corporation Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
EP1807157A2 (en) 2004-10-22 2007-07-18 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
NL1028134C2 (nl) 2005-01-27 2006-07-31 Sara Lee De Nv Werkwijze voor het bereiden van een voor consumptie geschikte drank uit ten minste twee op te lossen en/of te extraheren ingredienten en een hoeveelheid vloeistof.
TW200635542A (en) 2005-04-01 2006-10-16 Dharma Drum Mountain Method of establishing and using commemorative material
EP1885854B1 (en) * 2005-05-06 2012-10-17 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US20080280843A1 (en) 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
GB0520235D0 (en) 2005-10-05 2005-11-16 Astrazeneca Ab Method
AU2006305886C1 (en) * 2005-10-28 2011-03-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
PE20071240A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN200970210Y (zh) 2006-10-12 2007-11-07 王会才 拖把清洗脱水机

Similar Documents

Publication Publication Date Title
WO2006121960B1 (en) Methods and sequences to suppress primate huntington gene expression
JP2019519219A5 (enExample)
JP2024045199A (ja) 状態および疾患の処置のためのアンチセンスオリゴマー
WO2008021136B1 (en) Methods and sequences to suppress primate huntington gene expression in vivo
EP2516647B1 (en) Molecule for treating an inflammatory disorder
TWI901675B (zh) 用於病症及疾病之治療的opa1反義寡聚物
JP2014518612A5 (enExample)
EP4031147A1 (en) Methods of treatment of neurofibromatosis type 1 (nf1) and nf1-mediated conditions and compositions for use in such methods
JP2023501897A (ja) C9orf72関連疾患の治療のための三重機能アデノ随伴ウイルス(aav)ベクター
EP2246432A2 (en) Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
US20250059535A1 (en) Opa1 antisense oligomers for treatment of conditions and diseases
JP2025098252A (ja) 病態及び疾患の治療用アンチセンスオリゴマー
TW202329985A (zh) 用於治療cag重複序列疾病之組合物及方法
CN117377764A (zh) 多价寡核苷酸试剂及其使用方法
JP2020503014A5 (enExample)
JP2021534796A5 (enExample)
CN115210376A (zh) 诱导外显子51的跳读的反义核酸
JP6919891B2 (ja) Epstein−Barrウイルス関連癌に特異的な抗腫瘍剤
JP2019513395A5 (enExample)
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
JP2026502888A (ja) エピジェネティック調節因子の新規阻害剤
JP2024521767A5 (enExample)
JP2024529930A5 (enExample)
EP4357456A1 (en) Treatment of liver cancer or liver fibrosis
RU2839162C2 (ru) Молекула олигомерной нуклеиновой кислоты и ее применение